Salicylic acid

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided.

Uses and Indications

This drug is indicated for the removal of corns, calluses, plantar warts, and common warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. Following cleansing, the wart must be soaked in warm water for a duration of 5 minutes. After soaking, the area should be dried completely.

Using a brush or cotton swab, one drop of the medication should be applied at a time to ensure sufficient coverage of the wart. It is essential to allow the application to fully absorb and dry before proceeding.

This procedure may be repeated once or twice daily until the wart is completely removed.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. Additionally, individuals with known allergies to any of the product's ingredients should avoid use to prevent allergic reactions. The product should not be applied to moles, birthmarks, warts with hairs growing from them, genital warts, or warts located on the face or mucous membranes due to the potential for adverse effects.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin or any area that is infected or reddened. It should not be used on moles, birthmarks, warts with hairs growing from them, genital warts, or warts located on the face or mucous membranes.

Healthcare professionals should be aware of potential allergic reactions; patients with known allergies to any of the ingredients in this product should avoid its use.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients are advised to discontinue use and consult their healthcare provider if they become pregnant or are planning to become pregnant while using this product. Additionally, if discomfort persists, it is essential to seek medical advice.

Side Effects

For external use only. Patients are advised to discontinue use of the product if they become pregnant or are planning to become pregnant while using it. Additionally, if discomfort persists, patients should stop using the product and consult a healthcare professional. It is important for patients to seek medical advice under these circumstances to ensure their safety and well-being.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Corn Remover Mask. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients or those planning to become pregnant should discontinue use of the product. It is essential for these individuals to consult their healthcare provider if they become pregnant or are considering pregnancy while using the product. The potential risks associated with the use of this product during pregnancy have not been fully established, and appropriate medical guidance is necessary to ensure the safety of both the patient and the fetus.

Lactation

There is no information available regarding the use of this drug in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider this lack of data when advising lactating patients.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the lack of detailed guidance necessitates careful clinical judgment and individualized patient assessment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous assessment and supportive measures should be prioritized until the patient stabilizes or further treatment is determined.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is vital for ongoing management and potential reporting requirements.

Nonclinical Toxicology

The use of this product is contraindicated in individuals who are pregnant or planning to become pregnant, as there may be potential teratogenic effects associated with its use. No additional information regarding non-teratogenic effects, nonclinical toxicology, or animal pharmacology and toxicology is available.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center if the product is swallowed. It is important to instruct patients not to use the product on irritated skin or on any area that is infected or reddened.

Patients should be informed to disclose any known allergies to the ingredients in the product prior to use. Additionally, they should be cautioned against applying the product on moles, birthmarks, warts with hairs growing from them, genital warts, or warts located on the face or mucous membranes.

Healthcare providers should discuss the implications of using the product if the patient becomes pregnant or is planning to become pregnant during the course of treatment. Patients should be advised to report any persistent discomfort while using the product.

It is essential to instruct patients to avoid contact with the eyes. In the event that the product comes into contact with the eyes, they should flush the area with water for at least 15 minutes. Patients should also be cautioned to avoid inhaling vapors from the product.

Providers should remind patients to cap the bottle tightly after use and to store the product out of direct sunlight, at room temperature, and away from heat sources.

Storage and Handling

The product is supplied in a tightly capped bottle to ensure integrity. It should be stored out of direct sunlight and maintained at room temperature, away from heat sources. Proper handling includes ensuring the cap is secured after each use to prevent contamination and preserve the product's quality.

Additional Clinical Information

The product is administered topically, with the recommended frequency being once or twice daily until the wart is removed. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Wart Corn Remover Mask, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)